<DOC>
	<DOCNO>NCT00872586</DOCNO>
	<brief_summary>This study design evaluate additional efficacy safety olmesartan medoxomil/hydrochlorothiazide treatment Chinese patient mild moderate essential hypertension , fail attain blood pressure goal olmesartan medoxomil monotherapy</brief_summary>
	<brief_title>Evaluation Additional Efficacy , Safety Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg Treatment Chinese Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>At Visit 3 , mean seat diastolic blood pressure ( SeDBP ) ≥ 95 mmHg &lt; 110 mmHg , AND mean seat systolic blood pressure ( SeSBP ) ≥140 mmHg &lt; 180 mmHg At Visit 4 , mean SeDBP ≥ 90 mmH No significant disorder blood , kidney , liver , cardiovascular system endocrinology system Patients know suspect secondary hypertension Unstable angina History acute myocardial infarct , PTCA surgical cardiac procedure 3 month entry study Prior current congestive heart failure ( NYHA grade III IV ) , hypertrophic obstructive cardiomyopathy , valvular disease rheumatic heart disease Arrhythmia clinical significance Bilateral renal artery stenosis , isolate renal artery stenosis , post kidney transplantation Acute glomerular nephritis Gout sufferer , even normal serum uric acid entry Retinal hemorrhage /exudate Type 1 diabetes mellitus Uncontrolled type 2 diabetes mellitus Hypovolemia Patients autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>